Inicio
Resultado de la búsqueda
5 búsqueda de la palabra clave 'Transplantation'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis / Luz Natalia Builes Restrepo ; Andrés Felipe Escobar González
Título : Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González, Fecha de publicación : 2021 Títulos uniformes : Journal of Clinical Immunology Idioma : Inglés (eng) Palabras clave : Hemophagocytic lymphohistiocytosis hematopoietic stem cell transplantation child cyclophosphamide haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762 Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis [documento electrónico] / Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González, . - 2021.
Obra : Journal of Clinical Immunology
Idioma : Inglés (eng)
Palabras clave : Hemophagocytic lymphohistiocytosis hematopoietic stem cell transplantation child cyclophosphamide haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001687 AC-2021-013 Archivo digital Producción Científica Artículos científicos Disponible Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion / Marcos Arango Barrientos
Título : Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, Fecha de publicación : 2020 Títulos uniformes : Biology of Blood and Marrow Transplantation Idioma : Inglés (eng) Palabras clave : BK virus Cyclophosphamide Cystitis Haploidentical MESNA Transplantation Resumen : Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY. Mención de responsabilidad : Marcos Arango, Doris Cardona Referencia : Biol Blood Marrow Transplant. 2020 Aug;26(8):1492-1496 DOI (Digital Object Identifier) : 10.1016/j.bbmt.2020.04.028 PMID : 32417488 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1083879120302834 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5119 Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion [documento electrónico] / Marcos Arango Barrientos, . - 2020.
Obra : Biology of Blood and Marrow Transplantation
Idioma : Inglés (eng)
Palabras clave : BK virus Cyclophosphamide Cystitis Haploidentical MESNA Transplantation Resumen : Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY. Mención de responsabilidad : Marcos Arango, Doris Cardona Referencia : Biol Blood Marrow Transplant. 2020 Aug;26(8):1492-1496 DOI (Digital Object Identifier) : 10.1016/j.bbmt.2020.04.028 PMID : 32417488 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1083879120302834 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5119 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001376 AC-2020-054 Archivo digital Producción Científica Artículos científicos Disponible New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT / Luz Natalia Builes Restrepo
Título : New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, Fecha de publicación : 2020 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Palabras clave : tissue microarray transplantation trimethylamine hematopoietic stem cell transplantation Resumen : This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation–based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD. Mención de responsabilidad : Reem Elfeky, Giovanna Lucchini, Su-Han Lum, Giorgio Ottaviano, Natalia Builes, Zohreh Nademi, Alexandra Battersby, Terence Flood, Stephen Owens, Andrew J Cant, Helen Young, Sinéad Greener, Patrick Walsh, David Kavanagh, Srinivas Annavarapu, Kanchan Rao, Persis Amrolia, Robert Chiesa, Austen Worth, Claire Booth, Roderick Skinner, Bilyana Doncheva, Joseph Standing, Andrew R Gennery, Waseem Qasim, Mary Slatter, Paul Veys Referencia : Blood Adv. 2020 Jun 9;4(11):2418-2429. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2019001315 PMID : 32492158 En línea : https://ashpublications.org/bloodadvances/article/4/11/2418/460608/New-insights- [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5105 New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT [documento electrónico] / Luz Natalia Builes Restrepo, . - 2020.
Obra : Blood Advances
Idioma : Inglés (eng)
Palabras clave : tissue microarray transplantation trimethylamine hematopoietic stem cell transplantation Resumen : This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation–based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD. Mención de responsabilidad : Reem Elfeky, Giovanna Lucchini, Su-Han Lum, Giorgio Ottaviano, Natalia Builes, Zohreh Nademi, Alexandra Battersby, Terence Flood, Stephen Owens, Andrew J Cant, Helen Young, Sinéad Greener, Patrick Walsh, David Kavanagh, Srinivas Annavarapu, Kanchan Rao, Persis Amrolia, Robert Chiesa, Austen Worth, Claire Booth, Roderick Skinner, Bilyana Doncheva, Joseph Standing, Andrew R Gennery, Waseem Qasim, Mary Slatter, Paul Veys Referencia : Blood Adv. 2020 Jun 9;4(11):2418-2429. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2019001315 PMID : 32492158 En línea : https://ashpublications.org/bloodadvances/article/4/11/2418/460608/New-insights- [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5105 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001335 AC-2020-039 Archivo digital Producción Científica Artículos científicos Disponible A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America / Sergio Iván Hoyos Duque
Título : A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Fecha de publicación : 2018 Títulos uniformes : Clinics and Research in Hepatology and Gastroenterology Idioma : Inglés (eng) Palabras clave : Liver cancer epidemiology transplantation steatohepatitis Resumen : Background and aim: Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC) and liver transplantation (LT). Our study focused on changing trends of liver related HCC etiologies during the last years in Latin America.Methods: From a cohort of 2761 consecutive adult LT patients between 2005 and 2012 in 17 different centers, 435 with HCC were included. Different periods including years 2005—2006, 2007—2008, 2009—2010 and 2011—2012 were considered. Etiology of liver disease was confirmed in the explant. Results: Participating LT centers per country included 2 from Brazil (n = 191), 5 transplant programs from Argentina (n = 98), 2 from Colombia (n = 65), 4 from Chile (n = 49), 2 from Mexico (n = 12), and 1 from Peru (n = 11) and Uruguay (n = 9). Chronic hepatitis C infection was the leading cause of HCC in the overall cohort (37%), followed by HBV (25%) and alcoholic liver disease (17%). NAFLD and cryptogenic cirrhosis accounted for 6% and 7%, respectively. While HCV decreased from 48% in 2005—06 to 26% in 2011—12, NAFLD increased from 1.8% to 12.8% during the same period, accounting for the third cause of HCC. This represented a 6-fold increase in NAFLD-HCC, whereas HCV had a 2-fold decrease. Patients with NAFLD were older, had lower pre-LT serum AFP values and similar 5-year survival and recurrence rates than non NAFLD. Conclusion: There might be a global changing figure regarding etiologies of HCC in Latin America. This epidemiological change on the incidence of HCC in the world, although it has been reported, should still be confirmed in prospective studies. Mención de responsabilidad : Federico Piñero, Paulo Costa, Yuri Longatto Boteon, Sergio Hoyos Duque, Sebastian Marciano, Margarita Anders, Adriana Varón, Alina Zerega, Jaime Poniachik, Alejandro Soza, Martín Padilla Machaca, Josemaría Menéndez, Rodrigo Zapata, Mario Vilatoba, Linda Muñoz, Martín Maraschio, Luis G Podestá, Lucas McCormack, Adrian Gadano, Ilka S F Fatima Boin, Parente García, Marcelo Silva, Latin American Liver Research, Education, Awareness Network LALREAN Referencia : Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):443-452. DOI (Digital Object Identifier) : 10.1016/j.clinre.2018.03.014 PMID : 29773419 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2210-7401(18)30074-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4181 A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America [documento electrónico] / Sergio Iván Hoyos Duque, . - 2018.
Obra : Clinics and Research in Hepatology and Gastroenterology
Idioma : Inglés (eng)
Palabras clave : Liver cancer epidemiology transplantation steatohepatitis Resumen : Background and aim: Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC) and liver transplantation (LT). Our study focused on changing trends of liver related HCC etiologies during the last years in Latin America.Methods: From a cohort of 2761 consecutive adult LT patients between 2005 and 2012 in 17 different centers, 435 with HCC were included. Different periods including years 2005—2006, 2007—2008, 2009—2010 and 2011—2012 were considered. Etiology of liver disease was confirmed in the explant. Results: Participating LT centers per country included 2 from Brazil (n = 191), 5 transplant programs from Argentina (n = 98), 2 from Colombia (n = 65), 4 from Chile (n = 49), 2 from Mexico (n = 12), and 1 from Peru (n = 11) and Uruguay (n = 9). Chronic hepatitis C infection was the leading cause of HCC in the overall cohort (37%), followed by HBV (25%) and alcoholic liver disease (17%). NAFLD and cryptogenic cirrhosis accounted for 6% and 7%, respectively. While HCV decreased from 48% in 2005—06 to 26% in 2011—12, NAFLD increased from 1.8% to 12.8% during the same period, accounting for the third cause of HCC. This represented a 6-fold increase in NAFLD-HCC, whereas HCV had a 2-fold decrease. Patients with NAFLD were older, had lower pre-LT serum AFP values and similar 5-year survival and recurrence rates than non NAFLD. Conclusion: There might be a global changing figure regarding etiologies of HCC in Latin America. This epidemiological change on the incidence of HCC in the world, although it has been reported, should still be confirmed in prospective studies. Mención de responsabilidad : Federico Piñero, Paulo Costa, Yuri Longatto Boteon, Sergio Hoyos Duque, Sebastian Marciano, Margarita Anders, Adriana Varón, Alina Zerega, Jaime Poniachik, Alejandro Soza, Martín Padilla Machaca, Josemaría Menéndez, Rodrigo Zapata, Mario Vilatoba, Linda Muñoz, Martín Maraschio, Luis G Podestá, Lucas McCormack, Adrian Gadano, Ilka S F Fatima Boin, Parente García, Marcelo Silva, Latin American Liver Research, Education, Awareness Network LALREAN Referencia : Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):443-452. DOI (Digital Object Identifier) : 10.1016/j.clinre.2018.03.014 PMID : 29773419 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2210-7401(18)30074-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4181 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000795 AC-2018-082 Archivo digital Producción Científica Artículos científicos Disponible Hepatic transplantation in a child with giant multicystic tumor: pathological and imaging findings / María Elsy Sepúlveda Hincapie ; Nora Luz Yepes Palacio ; Sergio Iván Hoyos Duque
Título : Hepatic transplantation in a child with giant multicystic tumor: pathological and imaging findings Tipo de documento : documento electrónico Autores : María Elsy Sepúlveda Hincapie, ; Nora Luz Yepes Palacio, ; Sergio Iván Hoyos Duque, Fecha de publicación : 2010 Títulos uniformes : Pediatric Transplantation Idioma : Francés (fre) Palabras clave : Hepatic cystic tumor transplantation pathological imaging Resumen : A 30 month old male white child presented with 13 months of increasing abdominal girth. The MRI and MDCT showed a giant heterogeneous and predominantly cystic mass with thick and nodular septation, measuring approximately 18, 15, 20 cm, which occupied almost the whole liver. A histological diagnosis was not possible, which necessitated transplantation. One year after transplantation the course has been satisfactory without recurrence and with normal hepatic function and negative tumor markers Mención de responsabilidad : Germán A Castrillon, Elsy Sepúlveda, Nora L Yepez, Sergio Hoyos, Germán Osorio Referencia : Pediatr Transplantation 2010 Aug;14(5):e58-61. DOI (Digital Object Identifier) : 10.1111/j.1399-3046.2009.01166.x PMID : 19413715 En línea : https://onlinelibrary.wiley.com/doi/10.1111/j.1399-3046.2009.01166.x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3545 Hepatic transplantation in a child with giant multicystic tumor: pathological and imaging findings [documento electrónico] / María Elsy Sepúlveda Hincapie, ; Nora Luz Yepes Palacio, ; Sergio Iván Hoyos Duque, . - 2010.
Obra : Pediatric Transplantation
Idioma : Francés (fre)
Palabras clave : Hepatic cystic tumor transplantation pathological imaging Resumen : A 30 month old male white child presented with 13 months of increasing abdominal girth. The MRI and MDCT showed a giant heterogeneous and predominantly cystic mass with thick and nodular septation, measuring approximately 18, 15, 20 cm, which occupied almost the whole liver. A histological diagnosis was not possible, which necessitated transplantation. One year after transplantation the course has been satisfactory without recurrence and with normal hepatic function and negative tumor markers Mención de responsabilidad : Germán A Castrillon, Elsy Sepúlveda, Nora L Yepez, Sergio Hoyos, Germán Osorio Referencia : Pediatr Transplantation 2010 Aug;14(5):e58-61. DOI (Digital Object Identifier) : 10.1111/j.1399-3046.2009.01166.x PMID : 19413715 En línea : https://onlinelibrary.wiley.com/doi/10.1111/j.1399-3046.2009.01166.x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3545 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000115 AC-2010-047 Archivo digital Producción Científica Artículos científicos Disponible